Clarity is a breath away
aeoNose exhaled-breath analysis
Better diagnostics are just a breath away.
The eNose company aims to utilize the aeoNose, a portable breath analyzer, to overcome any obstacle that has thusfar prevented early detection of pathologies such as lung- and colon cancer. Our ultimate goal is to save lives and reduce the need for expensive and invasive tests and treatments.
-
Applicable as soon as earliest symptoms develop
-
Patient-friendly and completely painless
-
Highly reliable test
-
A lot cheaper compared to traditional diagnostic methods
-
A test only takes 15 minutes
-
Ease of use
Detecting diseases through exhaled breath
Detecting lung cancer using the aeoNose
The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.
STATUS OF THE VALIDATION PROCES ON LUNG CANCER DETECTION
Currently, the eNose Company is finishing up a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of lung cancer detection. Study results are expected to be ready over the course of 2021, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for lung cancer by the end of 2021.
Currently, we are validating the aeoNose in the following hospitals
Publications
Training and validating a portable electronic nose for lung cancer screening
R. Van de Goor,
M. van Hooren,
A.M. Dingemans,
B. Kremer en K. Kross
Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis
S. Kort,
M.M. Tiggeloven,
M. Brusse-Keizer,
J.W. Gerritsen,
J.H. Schouwink,
E. Citgez,
F.H.C. de Jongh,
S. Samii,
J. van der Maten,
M. van den Bogart en J. van der Palen
Improving lung cancer diagnosis by combining exhaled-breath data and clinical parameters
S. Kort,
M. M. Brusse-Keizer,
J.W. Gerritsen,
J.H. Schouwink,
E. Citgez,
F.H.C. de Jongh,
J. van der Maten,
S. Samii,
M. Van den Bogart en J. van der Palen
Detecting colorectal cancer using the aeoNose
The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.
STATUS OF THE VALIDATION PROCESS ON COLORECTAL CANCER DETECTION
Currently, the eNose Company is finishing up a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of colorectal cancer detection. Study results are expected to be ready over the course of 2021, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for colorectal cancer by the end of 2021.
Currently, we are validating the aeoNose in the following hospitals
Publications
Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer
K.E. van Keulen,
M.E. Jansen,
R.W.M. Schrauwen,
J.J. Kolkman en P.D. Siersema
Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: a pilot study
E.G.M. Steenhuis,
I.J.H. Schoenaker,
J.W.B. de Groot,
H.B. Fiebrich,
J.C. de Graaf,
R.M. Brohet,
J.D. van Dijk,
H.L. van Westreenen,
P.D. Siersema en W.H. de Vos tot Nederveen Cappel
Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device
Y. Peters,
R.W.M. Schrauwen,
A.C. Tan, S.K. Bogers,
B. de Jong, P.D. Siersema
COVID-19 detection using the aeoNose
The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.
STATUS OF THE VALIDATION PROCESS ON COVID-19 DETECTION
In close collaboration with ten hospitals in the Netherlands, the eNose Company is involved in a multi-center validation study on detecting COVID-19 using the aeoNose. Our goal is to develop a quick and accurate diagnostic test for healthcare workers. In addition we aim to demonstrate potential to apply the aeoNose as part of an early warning system by tracing and identifying future disease outbreaks.
Currently, we are validating the aeoNose in the following hospitals
Publications
FAQ
All exhaled-breath tests are being processed in a way that preserves anonymity by encryption. Actual classifications are visible in the electronic patient file only, and therefore not accessible by The eNose Company.
Results are stored in the electronic patient file and are only available to the patient and his/her healthcare professional.
Anonymized, numerical records of all screenings are encrypted and successively stored in an international BreathPrint™ database. Newly added breathprints contribute to improved, more accurate and smarter classification algorithms. In this way, this valuable source of information on exhaled-breath analysis of detectable diseases will be available to healthcare professionals around the globe.
Currently, a breath test for general practitioners is not available yet. However, development of such a test for GPs will start soon for a number of specific indications. At the moment, any trials for a self-test have not been planned.
In case the patient shows symptoms, the general practitioner or physician should consider performing the test, pending compatibility between symptoms and approved applications of the aeoNose.
The risk of cross-contamination is negligible. The following measures are in place to ensure this:
- For each test, a new disposable mouthpiece is used,
- For each mouthpiece, a so-called HEPA-filter is mounted, which filters out bacteria and viruses, thereby preventing them from entering the aeoNose device.
- The patient inhales and exhales through the (new, disposable) mouthpiece, not directly through the aeoNose. The AeoNose has been approved by departments for infection prevention in several Dutch hospitals, including in the case of Covid-19.
Click below to download the aeoNose user manual
The manual is intended for healthcare professionals who will be working with the aeoNose and can be downloaded free of charge.
